TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8179456
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (14 mg/d, increased to 21 mg/d if smoking more than seven cigarettes after 1 week)
Study: 2851195
Drug: Standard heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin, 5,000 I.U.
Study: 29110647
Drug: Omarigliptin 25
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omarigliptin 25 mg once-weekly
Study: 15621114
Drug: C(2) of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: C(2) of 1043 +/- 151 ng/mL or AUC(0-4) of 3146 +/- 262 ng . h/mL (with induction therapy)
Study: 15621114
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with basiliximab or thymoglobulin
Study: 11212082
Drug: Other GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Other GnRH agonists
Study: 30127595
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg alone
Study: 21394036
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg alone
Study: 30127595
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg and Amlodipine 10 mg co-administration
Study: 18369721
Drug: Two types
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two types of sex (vaginal plus oral or anal)
Study: 9603075
Drug: Pneumococcal vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal vaccine administered at 14 days post-splenectomy
Study: 8554468
Drug: Peroneal stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroneal stimulator (PS) during treatment period
Study: 2675496
Drug: Magnesium (Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (Mg 5‐longoral, Artesan GmbH)
Study: 30982447
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (2.0 × 10^8 CFU probiotics and 394 mg fructooligosaccharide)
Study: 20845670
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol (group T)
Study: 16144748
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg buprenorphine tablets (two 8 mg tablets)
Study: 16144748
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg buprenorphine solution (1 ml at 8 mg/ml)
Study: 11144006
Drug: Cisapride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (20 mg twice daily for 6 months)
Study: 10071518
Drug: cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine 10 mg
Study: 10071518
Drug: loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine 10 mg
Study: 2906345
Drug: LNG-containing pill
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-containing pill
Study: 2906345
Drug: GTD-containing pill
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTD-containing pill
Study: 28095580
Drug: 4% Hydroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% Hydroquinone lightening solution (OB)
Study: 25137843
Drug: Jiawei Shentong
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jiawei Shentong Zhuyu Decoction (JSZD), one dose per day, taken in two portions (morning and evening) for 30 days
Study: 25137843
Drug: Celecoxib Capsule
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib Capsule (200 mg once per day) and Mecobalamin Tablet (0.5 mg three times per day, only Mecobalamin from day 11) for 30 days
Study: 20384423
Drug: Nicotine (1.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (1.14 mg nicotine, 15.9 mg tar)
Study: 20384423
Drug: Denicotinized cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denicotinized cigarettes (.06 mg nicotine, 17.9 mg tar)
Study: 20384423
Drug: Alcohol (men:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (men: 0.8 g/kg; women: 0.7 g/kg)
Study: 18520312
Drug: Chronic care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic care intervention for depression treatment
Study: 7723385
Drug: Late intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late intensification plus monthly maintenance
Study: 1904551
Drug: Ribavirin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (20 mg per milliliter) administered continuously in aerosolized form
Study: 18292438
Drug: Clonidine infusion
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine infusion at a rate ranging from 6 to 10 microg x kg(‐1) x h(‐1)
Study: 10762110
Drug: Zanamivir 10
Normalized name: Zanamivir 10 mg/mL solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir 10 mg via Diskhaler twice daily for 5 days
Study: 9692103
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg b.d.)
Study: 8697891
Drug: Amoxycillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (1 g t.d.s.)
Study: 8207744
Drug: Verapamil 360
Normalized name: verapamil 360 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 360 mg per day
Study: 6376210
Drug: Oral N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral N-acetylcysteine (Fabrol)
Study: 3915163
Drug: Dipyridamole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (single dose)
Study: 3915163
Drug: Dipyridamole (multidose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (multidose, three times daily)
Study: 3915163
Drug: Placebo (multidose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multidose, three times daily)
Study: 24858952
Drug: Full rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full rapid-acting insulin dose
Study: 24858952
Drug: 50% reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% reduced rapid-acting insulin dose
Study: 18328014
Drug: Flaxseed (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (30 g daily for 3 months)
Study: 10100079
Drug: 0.02 mg
Normalized name: escin 0.02 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg ethinyloestradiol
Study: 10100079
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg oestrone sulphate
Study: 10100079
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg oestrone sulphate
Study: 10100079
Drug: High-dose oestrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oestrone
Study: 8914356
Drug: Topical fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluticasone propionate 0.05% cream
Study: 1796230
Drug: Ivermectin at
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin at 100 mcg/kg
Study: 25251800
Drug: Chest physical
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest physical therapy program
Study: 20136919
Drug: Topical Boswellic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Boswellic acids (0.5% BAs)
Study: 20136919
Drug: Placebo (base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (base cream without BAs)
Study: 10745577
Drug: Ticlopidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine treatment
Study: 365775
Drug: 500 IU
Normalized name: Vitamin E 500 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 IU of the influenza subunit vaccine
Study: 365775
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU of the influenza subunit vaccine
Study: 365775
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU of the influenza subunit vaccine
Study: 28278391
Drug: Indacaterol/glycopyrronium (110/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium (110/50 μg once daily)
Study: 28278391
Drug: Salmeterol/fluticasone (50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone (50/500 μg twice daily)
Study: 19028707
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg kg(‐1) of ketamine
Study: 1743250
Drug: Cefadroxil 15
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefadroxil 15 mg.kg‐1
Study: 1743250
Drug: Cefadroxil 5
Normalized name: cefadroxil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 5 mg.kg‐1 with Cephalexin 45 mg.kg‐1
Study: 6790688
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral feeding
Study: 11906804
Drug: Ketoconazole (600-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (600-900 mg daily)
Study: 30848096
Drug: 31 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 31 g of milk protein supplementation for 12 weeks
Study: 22128076
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral cyclophosphamide (DO)
Study: 405998
Drug: 10% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sodium cromoglycate ointment
Study: 405998
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (white soft-paraffin base only)
Study: 18553033
Drug: Tepid sponging
Normalized name: spongia tosta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepid sponging plus dipyrone (20 mg/kg) for 15 minutes
Study: 15724045
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg elemental zinc supplementation
Study: 15724045
Drug: Oral placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebos
Study: 11819193
Drug: Double caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double caudal injection versus single caudal injection
Study: 7574780
Drug: ACR‐CH (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACR‐CH (10 mg/person local injection)
Study: 7574780
Drug: ACR aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACR aqueous solution (10 mg/person local injection)
Study: 30060248
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of CKA up to 600 mg in humans
Study: 30060248
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of CKA in rats
Study: 23081753
Drug: BOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOC plus PegIFN/RBV using response-guided therapy (BOC/RGT)
Study: 23081753
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of anemia (EPO without RBV dose reduction)
Study: 23081753
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of anemia (RBV dose reduction without EPO)
Study: 23081753
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of anemia (EPO with RBV dose reduction)
Study: 23081753
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of anemia (neither RBV dose reduction nor EPO)
Study: 20846082
Drug: Electronic ASQ
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic ASQ (asthma screening questionnaire) using a tablet computer
Study: 18992654
Drug: Oral tolvaptan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tolvaptan, a vasopressin antagonist
Study: 22829919
Drug: Monthly sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulfadoxine-pyrimethamine (SP)
Study: 18008240
Drug: 2-dose sulfadoxine-pyrimethamine
Normalized name: Fansidar 500/25 (sulfadoxine / pyrimethamine) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose sulfadoxine-pyrimethamine (SP)
Study: 8491007
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg daily)
Study: 9071199
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg tid)
Study: 29107036
Drug: BA+CPT (Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA+CPT (Behavioral Activation + Cognitive Processing Therapy)
Study: 30554135
Drug: CPT (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT (Cognitive Processing Therapy)
Study: 27087678
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (OT) integrated with a self-administered stretching program
Study: 24886671
Drug: FOLFOX chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX chemotherapy strategy
Study: 8868311
Drug: Vehicle (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (50 ml isotonic saline)
Study: 1364939
Drug: Plain tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain tablets
Study: 4019267
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ascorbic acid three times daily during meals
Study: 31806216
Drug: Dabigatran dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dual therapy (110 mg twice daily)
Study: 31806216
Drug: Dabigatran dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dual therapy (150 mg twice daily)
Study: 26516724
Drug: Placebo DISKUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DISKUS DPI (twice daily)
Study: 23418668
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (2250 mg/day)
Study: 19189275
Drug: Classical massage
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical massage treatment (bi-weekly 30-min sessions for 5 weeks)
Study: 17697551
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with h-R3 (100 mg weekly intravenous infusion during radiotherapy)
Study: 15133322
Drug: 1.3 mg
Normalized name: menthol 1.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 mg of beta-cryptoxanthin (free)
Study: 15133322
Drug: 1.3 mg
Normalized name: menthol 1.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 mg of beta-cryptoxanthin (esters and free)
Study: 9163859
Drug: Deflazacort (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort (6 mg deflazacort to 5 mg prednisone ratio)
Study: 8201735
Drug: S boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: S boulardii (1 g/d for 4 weeks) with standard antibiotics
Study: 8201735
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with standard antibiotics
Study: 3146765
Drug: Sabeluzole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabeluzole (10 mg b.i.d. for 7 days)
Study: 21038021
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (Dexarhinaspray duo and nasal douche)
Study: 31361303
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy
Study: 12398148
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation plus preoperative preparation with 70% alcohol
Study: 2610502
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg per dose for 4 doses)
Study: 2610502
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg per dose for 3 doses)
Study: 2610502
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (625 mg)
Study: 12449294
Drug: Three servings
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three servings of yogurt added to daily diet
Study: 15536601
Drug: Glyburide treatment
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide treatment
Study: 27903262
Drug: Test mouthwash
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test mouthwash (0.25 mg/ml green tea and 7.82 mg/ml Salvadora persica L.)
Study: 18332449
Drug: Icodextrin 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icodextrin 1000 mL
Study: 18332449
Drug: Icodextrin 2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icodextrin 2500 mL
Study: 7880938
Drug: GHRH administration
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH administration
Study: 2970203
Drug: Mianserin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (60 mg daily)
Study: 6407502
Drug: Chlorimipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorimipramine (150 mg daily)
Study: 30587610
Drug: Placebo moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo moisturizing cream
Study: 16080808
Drug: ACE inhibitor-perindopril
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor-perindopril (+ diuretic-indapamide)
Study: 11136842
Drug: Raloxifene (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (higher dose)
Study: 11136842
Drug: Raloxifene (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (lower dose)
Study: 23651816
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment; n=22
Study: 16945045
Drug: TrimSpa (ephedra
Approvals — FDA: no, EMA: no, PMDA: no
Description: TrimSpa (ephedra 15 mg and caffeine 60 mg, 3 times/day for 7 days)
Study: 11406335
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg peroral ketoprofen
Study: 11406335
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg peroral ketoprofen
Study: 11406335
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg topical 2.5% ketoprofen gel
Study: 7920940
Drug: Mifepristone (RU486)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (RU486) 600 mg
Study: 25581159
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) 100 U/mL, subcutaneously, at doses of 0.4-0.8 U/kg for 6-12 days
Study: 14605997
Drug: Bolus rGLP-1
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus rGLP-1 injections at 1.5 nmol/kg
Study: 14605997
Drug: Continuous rGLP-1
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous rGLP-1 infusion at up to 4.5 pmol/kg/min
Study: 14605997
Drug: Continuous rGLP-1
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous rGLP-1 infusion in SU cohort
Study: 14605997
Drug: rGLP-1 infusions
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rGLP-1 infusions
Study: 10584647
Drug: Twice-daily heparin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily heparin flushes with once-weekly urokinase instillation (group B, n = 53)
Study: 10584647
Drug: Twice-daily heparin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily heparin flushes (group A, n = 52)
Study: 9257201
Drug: Dolasetron mesilate
Normalized name: Dolasetron mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesilate 25 mg
Study: 9257201
Drug: Dolasetron mesilate
Normalized name: Dolasetron mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesilate 50 mg
Study: 9257201
Drug: Dolasetron mesilate
Normalized name: Dolasetron mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesilate 100 mg
Study: 8911112
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg x 3 or 8 mg x 4)
Study: 3053313
Drug: Acarbose (BAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (BAY g 5421)
Study: 31179773
Drug: Oral mucoadhesive
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mucoadhesive film containing chitosan
Study: 27912735
Drug: Edmonston-Zagreb measles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb measles vaccine at 4.5 and 9 months (group A)
Study: 27912735
Drug: Edmonston-Zagreb measles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb measles vaccine at 4.5 months (group A)
Study: 27912735
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine at 4.5 months and Edmonston-Zagreb measles vaccine at 9 months (group B)
Study: 27912735
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine at 4.5 months and Schwarz measles vaccine at 9 months (group C)
Study: 24040472
Drug: Negatively-charged aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negatively-charged aerosol therapy (2 hours per time, twice a day)
Study: 24040472
Drug: Normal, routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal, routine treatment
Study: 16809801
Drug: Single-dose ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose ritonavir 100 mg
Study: 3497039
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tenoxicam
Study: 7983661
Drug: 500-1000 mg
Normalized name: ampicillin 1000 MG / sulbactam 500 MG [Unasyn]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-1000 mg naproxen
Study: 31838180
Drug: Lindioil ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lindioil ointment
Study: 23327021
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (dexamethasone, acetaminophen codeine, placebo)
Study: 18760982
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (self-monitoring daily pedometer-determined step count)
Study: 7762844
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac and IA bupivacaine